Menu
Search
|

Menu

Close
X

Heron Therapeutics Inc HRTX.OQ (NASDAQ Stock Exchange Capital Market)

19.14 USD
-- (--)
As of Jul 17
Previous Close 19.14
Open --
Volume --
3m Avg Volume 345,573
Today’s High --
Today’s Low --
52 Week High 41.55
52 Week Low 16.20
Shares Outstanding (mil) 79.19
Market Capitalization (mil) 1,515.78
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.45 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY19
32
FY18
77
FY17
31
FY16
1
EPS (USD)
FY19
-0.804
FY18
-2.472
FY17
-3.649
FY16
-4.551
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.16
Price to Sales (TTM)
vs sector
15.55
8.16
Price to Book (MRQ)
vs sector
4.56
4.38
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
1.45
18.17
LT Debt to Equity (MRQ)
vs sector
0.00
13.01
Return on Investment (TTM)
vs sector
-87.02
12.64
Return on Equity (TTM)
vs sector
-89.42
17.19

EXECUTIVE LEADERSHIP

Kevin Tang
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
Barry Quart
President, Chief Executive Officer, Director, Since 2019
Salary: $614,414.00
Bonus: --
Robert Hoffman
Chief Financial Officer, Senior Vice President - Finance, Since 2017
Salary: $357,438.00
Bonus: --
Kimberly Manhard
Executive Vice President - Drug Development, Since 2016
Salary: $466,796.00
Bonus: --
David Szekeres
Senior Vice President, General Counsel, Business Development, Corporate Secretary, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4242 Campus Point Ct Ste 200
SAN DIEGO   CA   92121

Phone: +1858.2514400

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

SPONSORED STORIES